BlackRock Inc. Takes $3.63 Million Position in Armata Pharmaceuticals, Inc. $ARMP

Key Points

• BlackRock acquired 559,986 shares of Armata Pharmaceuticals in the second quarter, worth approximately $3.63 million and representing a 1.53% stake. Institutional investors and hedge funds collectively own 3.57% of the company.
• Analyst sentiment is moderately positive: two analysts rate Armata a Buy and one rates it Hold, while the consensus price target is $15.00. Zacks Research recently upgraded the stock to Hold.
• Armata reported a quarterly loss of $0.27 per share, beating estimates for a $0.44 loss, and revenue of $2.51 million versus a $0.40 million consensus estimate. The clinical-stage biotech develops bacteriophage therapies targeting antibiotic-resistant infections.

BlackRock Inc. bought a new stake in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 559,986 shares of the company's stock, valued at approximately $3,629,000. BlackRock Inc. owned 1.53% of Armata Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Deutsche Bank AG purchased a new position in shares of Armata Pharmaceuticals in the 2nd quarter valued at about $78,000. Jane Street Group LLC purchased a new stake in shares of Armata Pharmaceuticals during the fourth quarter worth approximately $108,000. Bank of America Corp DE increased its stake in shares of Armata Pharmaceuticals by 233.2% during the first quarter. Bank of America Corp DE now owns 11,714 shares of the company's stock worth $120,000 after buying an additional 8,198 shares during the period. Millennium Management LLC acquired a new stake in Armata Pharmaceuticals in the fourth quarter valued at approximately $164,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in Armata Pharmaceuticals in the fourth quarter valued at approximately $177,000. 3.57% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded shares of Armata Pharmaceuticals to a "hold" rating in a report on Monday, May 18th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $15.00.

Armata Pharmaceuticals Price Performance

NYSEAMERICAN ARMP opened at $5.84 on Friday. The company has a fifty day moving average of $4.99 and a two-hundred day moving average of $7.87. The company has a market capitalization of $217.13 million, a PE ratio of -0.77 and a beta of 1.34. Armata Pharmaceuticals, Inc. has a 1 year low of $2.76 and a 1 year high of $16.34.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.17. The business had revenue of $2.51 million during the quarter, compared to the consensus estimate of $0.40 million. Armata Pharmaceuticals had a negative return on equity of 12.24% and a negative net margin of 3,467.04%. On average, research analysts expect that Armata Pharmaceuticals, Inc. will post 0.5 earnings per share for the current year.

Armata Pharmaceuticals Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company's proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata's pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.